Lung cancer is the leading cause of cancer-related mortality worldwide, accounting for 19% of cancerrelated deaths.
1 This devastating toll is the consequence of a high incidence (1·8 million new diagnoses in 2012) and a low rate of cure. Most patients continue to be diagnosed at advanced disease stages. Moreover, the outcome of patients who present with resectable and operable lung cancer (about 25% of cases) is substantially worse than that noted in many other earlystage solid tumours, with most patients eventually developing systemic relapse.
Based on the ability of systemic chemotherapy to improve outcome in advanced non-small-cell lung cancer (NSCLC), treatment strategies complementary to radical surgery, including adjuvant and neoadjuvant cytotoxic treatment, have been extensively studied. Indeed, postoperative chemotherapy has been consistently shown to prevent recurrences and increase survival in many clinical trials. The most recent publication of the NSCLC Meta-analysis Collaborative Group, based on 34 trials and 8447 patients, showed an absolute survival improvement at 5 years of 4% (hazard ratio [HR] 0·86, 0·81-0·92).
2 Another meta-analysis that comprised fi ve recent large trials (4584 patients), assessing cisplatin-based chemotherapy, estimated a 5 year survival benefi t of 5·4% for patients receiving adjuvant therapy compared with those that underwent surgery alone (0·89, 0·82-0·96). Consequently, adjuvant cisplatin-based chemotherapy has been widely adopted as the standard of care for patients with resected lung cancer. Evidence to support the use of adjuvant tegafur-uracil is mostly restricted to patients of east Asian origin with early-stage adenocarcinoma. 4 In The Lancet, Sarah Burdett and colleagues 5 report a systematic review and individual patient data meta-analysis on the eff ect of preoperative chemotherapy with subsequent surgery compared with surgery alone. The meta-analysis has been well conducted, included most randomised controlled trials (15) and patients (2385) treated in this context, and the results are scientifi cally sound and relevant for routine clinical practice. This analysis formally confi rms that neoadjuvant chemotherapy improves overall survival to a similar extent as adjuvant treatment (HR 0·87, 95% CI 0·78-0·96; or an increment in 5 year survival rate from 40% to 45%). This eff ect was essentially due to a reduction in distant recurrence rate (0·69, 0·58-0·82), since no clear eff ect on locoregional failure was evident (0·88, 0·73-1·07). Subgroup analysis suggested no diff erential eff ect on the basis of chemotherapy regimen used (number of drugs or treatment courses, platinum analogue employed), adjuvant radiotherapy received, or other patient and tumour characteristics. However, the robustness of these subanalyses is limited because some subsets of patients were scarcely represented (eg, stage IA or III).
This meta-analysis more defi nitively substantiates the value of preoperative chemotherapy than individual trials or literature-based meta-analyses. 6 Indirect comparisons with adjuvant studies suggest a similar eff ect on survival (4-5% absolute gain at 5 years), although populations of patients might not be comparable because patients included in neoadjuvant trials probably had a higher risk of recurrence. Concordant with these data, three small studies that compared neoadjuvant with perioperative or postoperative chemotherapy in early-stage NSCLC showed similar outcomes for these diff erent treatment strategies. [7] [8] [9] Similarly, the sequence of local and systemic treatment does not seem to aff ect cure rates in other disease settings such as osteosarcoma, or breast or bladder cancer, although preoperative treatment spares the need for more radical and mutilating surgery in some patients.
10 However, the rates of resectability or the need for pneumonectomy did not seem to improve with neoadjuvant treatment strategies in NSCLC patients. [7] [8] [9] One could speculate that this diff erential outcome might be conditioned by the lower sensitivity of NSCLC to available systemic therapies.
Planned treatment delivery and dose intensity is consistently higher if chemotherapy is given preoperatively. Better tolerance and treatment adherence are relevant factors to consider when deciding the optimum timing of chemotherapy, particularly since systemic treatment does not increase early mortality rates after surgery. Based on these considerations, patients that are sure candidates for complementary chemotherapy, such as those with T3 (or T2 >4 cm) tumours or N1 disease, might be the ideal candidates for a neoadjuvant approach, particularly if defi nitive surgery is anticipated to be delayed.
Nevertheless, despite the benefi t shown, only one of 13 patients with early-stage lung cancer actually benefi ts from complementary chemotherapy, and at the expense of inducing relevant side-eff ects in all treated patients. There is therefore an urgent need to develop predictive biomarkers to identify those patients who will profi t from systemic treatment. In view of most recent results, it seems unlikely that a single gene or even more complex gene signatures will be ready for use in clinical practice in the near future, although some trials in progress are currently trying to address this issue. More probably, in our opinion, selected subgroups of patients with lung cancer with specifi c genomic alterations (ie, tumours with activating EGFR mutations or ALK gene rearrangements) might derive larger benefi ts from targeted therapies (ie, gefi tinib, erlotinib, or crizotinib) that have already been proven to aff ect the natural history of advanced-stage disease. 11, 12 Indeed, specifi c therapies directed against other oncogenedriven solid tumours, with proven eff ectiveness in the metastatic setting, have subsequently shown a substantial eff ect in adjuvant or neoadjuvant settings. 13 Studies testing such a hypothesis in NSCLC are ongoing, but available data so far are contradictory and do not support implementation in routine clinical practice at present. Awareness is growing that tuberculosis is a major cause of disease and death in children from areas endemic with tuberculosis, but its contribution is poorly quantifi ed because of diagnostic diffi culties in resource-limited settings.
1 Globally, in 2011, an estimated 1·3 million deaths in children were attributed to pneumonia.
2 Most of these deaths occurred in areas endemic with tuberculosis, where the actual cause of death was rarely verifi ed. Autopsy studies identifi ed tuberculosis in 11% of children infected with HIV, and 8% of children not infected with HIV who died from respiratory disease in fi ve African countries.
3 Tuberculosis might also be an underlying cause of death in children dying from meningitis, sepsis, HIV/AIDS, or severe malnutrition, and its relative contribution to child morbidity and mortality is likely to increase if widespread rollout of Haemophilus infl uenza type B, pneumococcal, and rotavirus vaccines reduces the eff ect of these diseases. 4 An emerging threat is the rise of drug-resistant tuberculosis, which poses a major challenge to global tuberculosis control eff orts.
5 WHO estimates that 450 000 (range 300 000-600 000) cases of multidrugresistant tuberculosis (resistant to isoniazid and rifampicin) occurred in 2012, with less than 20% (77 000) of cases receiving appropriate treatment. 6 Failure to treat infectious multidrug-resistant tuberculosis cases facilitates ongoing transmission of drug-resistant strains and exposes vulnerable young children to infection. 7 Crude projections estimate that roughly 10% of the global tuberculosis disease burden occurs in children, 8 suggesting that around 45 000 paediatric multidrug-resistant tuberculosis cases occurred in 2012. However, such estimates are diffi cult to verify and fail to account for variability in the paediatric tuberculosis burden, which depends on the level of epidemic control achieved, the use of preventive therapy, and the population demographics in particular areas. 9 In the absence of reliably reported data, accurate assessment of the paediatric disease burden requires evidence-based extrapolation from existing data and consideration of regional variation.
A study by Helen Jenkins and colleagues 10 in The Lancet creatively combines three elements to estimate the number of incident tuberculosis and multidrug-resistant tuberculosis cases in children by WHO region. First, the authors did a systematic literature review to describe the relation between multidrug-resistant tuberculosis in children and treatment-naive adults, excluding studies in which children with drug-resistant tuberculosis were more likely to be included, such as outbreak and contact investigations. The proportions of multidrugresistant tuberculosis cases were similar (estimated slope of regression line 1·0691) in treatment-naive adults and in children with tuberculosis, showing that both groups represent local transmission of multidrug-resistant tuberculosis, consistent with previous observations. 11 Country-level estimates of multidrug-resistant tuberculosis in treatment-naive adults then guided estimates of the proportion of child tuberculosis cases with multidrug-resistant tuberculosis, providing a neat solution to the absence of reliable data for multidrug-resistant tuberculosis in children.
Second, the authors adjusted sputum smear-positive cases reported to WHO by a factor that accounts for the expected age-specifi c proportions of sputum smear-positive disease. Because some countries failed to report age-disaggregated data to WHO, Jenkins and colleagues fi tted a logistic regression model with the estimated proportion of paediatric tuberculosis cases as the dependent variable and the log 10 of the estimated tuberculosis incidence as the explanatory variable. The estimated percentage of tuberculosis cases in children aged younger than 15 years varied from 8% to 12%,
